EIGHTH SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”), dated as of March 19, 2010, among NEW BINAX, INC., NEW BIOSITE INCORPORATED, ALERE NEWCO, INC. AND ALERE NEWCO II, INC. (collectively, the “New Guarantors”), Subsidiaries of Inverness...Eighth Supplemental Indenture • March 19th, 2010 • New Binax, Inc. • New York
WHEREAS the Issuer has heretofore executed and delivered to the Trustee an Indenture dated as of May 12, 2009, as amended, supplemented and modified by a First Supplemental Indenture dated as of May 12, 2009, a Second Supplemental Indenture dated as of June 9, 2009, a Third Supplemental Indenture dated as of August 4, 2009, a Fourth Supplemental Indenture dated as of September 22, 2009, a Fifth Supplemental Indenture dated as of November 25, 2009, a Sixth Supplemental Indenture dated as of February 1, 2010, and a Seventh Supplemental Indenture dated as of March 1, 2010 (as so amended, supplemented and modified, and as further amended, supplemented or modified to date, the “Indenture”), by and among the Issuer, the Existing Guarantors and the Trustee, providing for the issuance of 9.00% Senior Subordinated Notes due 2016 (the “Notes”);
ELEVENTH SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”), dated as of March 19, 2010, among NEW BINAX, INC., NEW BIOSITE INCORPORATED, ALERE NEWCO, INC., AND ALERE NEWCO II, INC. ( the “New Guarantors”), Subsidiaries of Inverness Medical...Supplemental Indenture • March 26th, 2010 • New Binax, Inc. • In vitro & in vivo diagnostic substances • New York
WHEREAS the Issuer has heretofore executed and delivered to the Trustee an Indenture dated as of August 11, 2009, as amended, supplemented and modified by a Third Supplemental Indenture dated as of September 28, 2009, a Fifth Supplemental Indenture dated as of November 25, 2009, a Seventh Supplemental Indenture dated as of February 1, 2010, and a Ninth Supplemental Indenture dated as of March 1, 2010 (as so amended, supplemented or modified, and as further amended, supplemented or modified to date, the “Indenture”), by and among the Issuer, the Existing Guarantors and the Trustee, providing for the issuance of 7.875% Senior Notes due 2016 (the “Notes”);
NINTH SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”), dated as of March 1, 2010, among LABORATORY SPECIALISTS OF AMERICA, INC., KROLL LABORATORY SPECIALISTS, INC., and SCIENTIFIC TESTING LABORATORIES, INC. ( the “New Guarantors”), Subsidiaries...Supplemental Indenture • March 26th, 2010 • New Binax, Inc. • In vitro & in vivo diagnostic substances • New York
WHEREAS the Issuer has heretofore executed and delivered to the Trustee an Indenture dated as of August 11, 2009, as amended, supplemented and modified by a Third Supplemental Indenture dated as of September 28, 2009, a Fifth Supplemental Indenture dated as of November 25, 2009, and a Seventh Supplemental Indenture dated as of February 1, 2010 (as so amended, supplemented or modified, and as further amended, supplemented or modified to date, the “Indenture”), by and among the Issuer, the Existing Guarantors and the Trustee, providing for the issuance of 7.875% Senior Notes due 2016 (the “Notes”);
EIGHTH SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”), dated as of March 1, 2010, among LABORATORY SPECIALISTS OF AMERICA, INC., KROLL LABORATORY SPECIALISTS, INC., and SCIENTIFIC TESTING LABORATORIES, INC. (the “New Guarantors”), Subsidiaries...Eighth Supplemental Indenture • March 26th, 2010 • New Binax, Inc. • In vitro & in vivo diagnostic substances • New York
WHEREAS the Issuer has heretofore executed and delivered to the Trustee an Indenture dated as of August 11, 2009, as amended, supplemented and modified by a First Supplemental Indenture dated as of August 11, 2009, a Second Supplemental Indenture dated as of September 22, 2009, a Fourth Supplemental Indenture dated as of November 25, 2009, and a Sixth Supplemental Indenture dated as of February 1, 2010 (as so amended, supplemented or modified, and as further amended, supplemented or modified to date, the “Indenture”), by and among the Issuer, the Existing Guarantors and the Trustee, providing for the issuance of 7.875% Senior Notes due 2016 (the “Notes”);
TENTH SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”), dated as of March 19, 2010, among NEW BINAX, INC., NEW BIOSITE INCORPORATED, ALERE NEWCO, INC., AND ALERE NEWCO II, INC. (the “New Guarantors”), Subsidiaries of Inverness Medical...Tenth Supplemental Indenture • March 26th, 2010 • New Binax, Inc. • In vitro & in vivo diagnostic substances • New York
WHEREAS the Issuer has heretofore executed and delivered to the Trustee an Indenture dated as of August 11, 2009, as amended, supplemented and modified by a First Supplemental Indenture dated as of August 11, 2009, a Second Supplemental Indenture dated as of September 22, 2009, a Fourth Supplemental Indenture dated as of November 25, 2009, a Sixth Supplemental Indenture dated as of February 1, 2010, and an Eighth Supplemental Indenture dated as of March 1, 2010 (as so amended, supplemented or modified, and as further amended, supplemented or modified to date, the “Indenture”), by and among the Issuer, the Existing Guarantors and the Trustee, providing for the issuance of 7.875% Senior Notes due 2016 (the “Notes”);
